1527-17-9

Usage

Uses

Used in Pharmaceutical Industry:
2-[2-(Phenylthio)phenyl]acetic acid is used as a potential pharmaceutical compound for its possible bioactivity, which could be harnessed for the development of new drugs. The presence of the phenylthio group may contribute to its interaction with biological targets, making it a candidate for further exploration in drug discovery.
Used in Chemical Research:
In the field of chemical research, 2-[2-(Phenylthio)phenyl]acetic acid serves as a subject for studying the effects of molecular structure on chemical reactivity and stability. Its phenylthio group and aromatic rings provide a basis for investigating the influence of these functional groups on the compound's properties and potential applications.
Used in Material Science:
2-[2-(Phenylthio)phenyl]acetic acid may be utilized in material science as a component in the synthesis of new materials with specific properties. 2-[2-(PHENYLTHIO)PHENYL]ACETIC ACID's aromaticity and the presence of the phenylthio group could contribute to the development of materials with tailored characteristics for various applications, such as in electronics or as specialty coatings.

InChI:InChI=1/C14H12O2S/c15-14(16)10-11-6-4-5-9-13(11)17-12-7-2-1-3-8-12/h1-9H,10H2,(H,15,16)

Upstream product

• 13963-35-4 2-(phenylthio)toluene 
• 37660-43-8 2-(phenylthio)benzyl bromide 
• 108-98-5 thiophenol 
• 66370-75-0 methyl (2-iodophenyl)acetate 
• 37527-78-9 (2-phenylsulfanyl-phenyl)-acetic acid methyl ester 
• 945-51-7 1,1'-sulfinylbisbenzene 
• 18698-96-9 o-iodophenylacetic acid 
• 1527-13-5 2-Phenylthiobenzoesaeureethylester 
• 1527-15-7 2-(phenylthio)benzyl chloride 
• 1527-12-4 2-(phenylthio)benzoic acid 
• 1527-14-6 phenyl 2-hydroxymethylphenyl sulfide 
• 88-67-5 2-Iodobenzoic acid 
• 1527-16-8 2-phenylthiophenylacetonitrile 

Downstream Products

• 37527-78-9 (2-phenylsulfanyl-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Redox-Neutral α-Arylation of Alkyl Nitriles with Aryl Sulfoxides: A Rapid Electrophilic Rearrangement

A facile α-arylation of nitriles has been developed by simply introducing Tf2O and DABCO to the mixture of nitriles and aryl sulfoxides. The transformation consists of two sequential steps: (i) Tf2O-initiated electrophilic assembly a

A Cu-Catalysed Radical Cross-Dehydrogenative Coupling Approach to Acridanes and Related Heterocycles

The synthesis of acridanes and related compounds through a Cu-catalysed radical cross-dehydrogenative coupling of simple 2-[2-(arylamino)aryl]malonates is reported. This method can be further streamlined to a one-pot protocol involving the in situ fomation of the 2-[2-(arylamino)aryl]malonate by α-arylation of diethyl malonate with 2-bromodiarylamines under Pd catalysis, followed by Cu-catalysed cyclisation.

Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

Malaria remains a significant infectious disease with even artemisinin-based therapies now facing resistance in the field. Development of new therapies is urgently needed, either by finding new compounds with unique modes of action, or by reversing resistance towards known drugs with 'chemosensitizers' or 'chemoreversal' agents (CRA). Concerning the latter, we have focused on the resistance mechanisms developed against chloroquine (CQ). We have synthesized a series of compounds related to previously identified CRAs, and found promising novel compounds. These compounds show encouraging results in a coumarin labeled chloroquine uptake assay, exhibiting a dose response in resensitising parasites to the antimalarial effects of chloroquine. Selected compounds show consistent potency across a panel of chloroquine and artemisinin sensitive and resistant parasites, and a wide therapeutic window. This data supports further study of CRAs in the treatment of malaria and, ultimately, their use in chloroquine-based combination therapies.

Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity

A targeted library of substituted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines (prototypes I, II and III), and structurally analogous to tamoxifen have been synthesized as a new class of anti-breast cancer agents. All the prototype molecules exhibited potential antiproliferative activity against ER + ve and ER-ve breast cancer cell lines. Dibenzo[b,f]thiepine prototypes were found to be more active. Of all the compound tested, 14b exhibited potent in-vitro antiproliferative activity at 1.33 μM and 5 μM concentration in MCF-7 and MDA-MB-231 cell lines and was devoid of any cytotoxicity in normal HEK cells even at 50 μM. Cell cycle analysis showed that the compound 14b inhibited cell proliferation due to G0/G1 arrest in MCF-7 cells. Annexin-V FITC and PI staining experiments confirmed that the cell inhibition was primarily due to apoptosis and not by necrosis, which was also supported by LDH release assay experiment. Molecular docking studies showed better binding interaction of the new dibenzo[b,f]thiepine analogue 14b with the estrogen receptor (ER) as compared to 4-hydroxy-tamoxifen and this enhanced binding might be responsible for its estrogen antagonistic activity that induces cell cycle arrest, apoptosis and inhibition of breast cancer cells.

SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.